Client Testimonials



"With their systematic review of the key drivers of innovation and risk, Catenion has helped us focus our early stage medical devices and technology portfolios on the most promising assets . Their approach of on–the–job training our portfolio managers in the methodology and staying in the background led to great acceptance in the organization. As a result, we have decided to implement their approach. I have worked with Catenion for many years and in various roles and have always highly valued their contribution."

Dr. Ulrich Thibaut
Mitglied des Vorstandes (CTO)
Drägerwerk AG

"Catenion’s approach to assessing risk and value on both a project and portfolio level goes way beyond what is usually discussed in senior executive teams. It has allowed us to create a very solid foundation of information, which is the key to understanding the portfolio. Their process and independent points of view have greatly helped our Executive Management Board take difficult decisions during a challenging post–merger review of the portfolio, and going forward we have decided to implement their approach as the framework for us to manage our portfolio."

Vincent Aurentz
Executive Vice President
Business Development and Portfolio Management
Merck Serono

"We have successfully used Catenion for R&D portfolio management and strategy support. Catenion’s in–depth understanding of pharmaceutical R&D and their sharp analytical approach clearly differentiates them. Our collaboration has been efficient, valuable and constructive."

Dr. Claus Braestrup
Former President and CEO
H. Lundbeck A/S

"I tremendously enjoyed working with Catenion. They are fully at home in pharmaceutical Discovery and bring a highly unusual combination of a rigorous analytical mind–set with a pragmatic understanding of R&D strategy and organisational mechanics."

Dr. Gianni Gromo
Global Head Metabolic & Vascular Disease Area
F. Hoffmann–La Roche AG

"One of the toughest decisions I had to take in my role as CEO of Bayer Pharma was to refocus our Discovery activities after the market withdrawal of Lipobay. Using their proprietary tools, benchmarks and a tough, fact–based approach, Catenion guided the Discovery management team through a difficult process of prioritisation of therapeutic areas and projects and provided crucial support for the decision making of the Bayer Corporate Board."

Dr. Wolfgang Plischke
Member of the Board of
Management of Bayer AG
Previously CEO of Bayer Pharma

"Over the years, I have come to know Catenion as independent thinkers who use their insights and methodological sophistication to come up with creative solutions that work."

Bert Tjeenk Willink, M.D.
Head of Corporate Board
Division Pharma Marketing and Sales
Boehringer Ingelheim